The frequently observed adverse events and laboratory abnormalities in LONSURF plus bevacizumab-treated patients (occurring in ≥20% of cases) included neutropenia, anemia, thrombocytopenia, fatigue, nausea, increased AST, increased ALT, increased alkaline phosphatase, low sodium, diarrhea, abdominal pain, and decreased appetite (31). Here, GPT is linked to anemia (phenotype).